Antengene announces approval of the phase ii study of selinexor for the treatment of myelofibrosis in china

Shanghai and hong kong, aug. 23, 2021 /prnewswire/ -- antengene corporation limited ("antengene", sehk: 6996.hk), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that china's national medical products administration has approved a phase ii study of selinexor (xpovio®) for the treatment of patients with myelofibrosis (mf). mf is a clonal bone narrow neoplasm which can emerge either as primary mf (pmf), polycythemia vera (pv) or essential thrombocythemia (et).
KPTI Ratings Summary
KPTI Quant Ranking